Back

Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Clinical Outcomes in Patients with Hypertrophic Cardiomyopathy

29 August 2026 (08:15 - 09:00)
Organised by: Logo
Congress Presentation Part of: Improving diagnosis and treatment in hypertrophic cardiomyopathy Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Sung-Hee Shin

Inha University Hospital, Incheon (Korea (Republic of))

5 More presentations in this session

Presentation thumbnail
Mavacamten versus septal ablation: prognostic differences in 1-year cardiovascular events for HOCM with resting LVOTG ≥50 mmHg
Doctor B. Huang (Chongqing, CN)
Abstract Slides Video
Presentation thumbnail
Baseline global longitudinal strain and mechanical dispersion predict ejection fraction decline during mavacamten therapy in obstructive hypertrophic cardiomyopathy
Doctor I. Cergan (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
Impact of peak provoked left ventricular outflow tract gradients on health-related quality of life in patients with hypertrophic cardiomyopathy: a real-world cross-sectional survey
Doctor P. Gebrehiwet (South San Francisco, US)
Abstract Slides Video
Presentation thumbnail
Heterogeneous left atrial strain trajectories during mavacamten therapy in obstructive hypertrophic cardiomyopathy
Doctor D. Jensen (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
MRI-derived wall thickness heterogeneity in hypertrophic cardiomyopathy and in carriers of sarcomeric gene mutations
Doctor R. Licordari (Messina, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Improving diagnosis and treatment in hypertrophic cardiomyopathy

The Event

Event poster

ESC Congress 2026

29 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of SGLT2 inhibitors on diastolic function in patients with non-obstructive hypertrophic cardiomyopathy
29 June 2021
thumbnail
Congress Presentation
Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis
27 August 2021
thumbnail
Congress Presentation
Distinct phenotypic groups and related clinical outcomes in patients with hypertrophic cardiomyopathy
12 December 2024
thumbnail
Webinar
SGLT2 inhibitors across the left ventricular function spectrum
24 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources